Rockland and LIMR Expand Licensing and Commercialization Relationship
News Oct 30, 2012
Rockland Immunochemicals Inc., has announced the expansion of a licensing and commercialization relationship with Lankenau Institute for Medical Research (LIMR) through its business development subsidiary LIMR Development, Inc. (LDI). Instrumental in advancing this relationship was Carl Leighton of Wildwood Capital.
According to a new agreement, Rockland Immunochemicals will market established technologies including the CellCountEZ®, OxPhos™, RadDose™ and the Intracellular ThiolEZ™ assays.
George Prendergast, PhD, President and CEO of LIMR stated: “We have been very pleased with our partnership with Rockland and are looking forward to continued success within this expanded relationship.”
"LIMR's independent research encompassing cancer and inflammation elegantly enhances Rockland's antibody portfolio and technology platform. It is my belief that the new products included in our expanded licensing and commercialization agreement will enhance our ability to bring unique scientific opportunities to the global research community," commented James Fendrick, President and CEO of Rockland Immunochemicals.
Included in the additional product lines will be the CellCountEZ® assay measuring metabolically active cells while simultaneously quantifying cell death to determine cell viability, cell toxicity or cellular proliferation.
The OxPhos™ assay is capable of determining the cellular glutathione recycling capacity in tissue culture as well as that of whole blood, thus providing insight into oxidative stress during the aging process, antioxidant levels upon delivery of chemotherapy regime and toxicology.
The RadDose™ assay is used for the measurement of ionizing radiation dose rates, while the Intracellular ThiolEZ™ assay is capable of determining total intracellular thiols, including glutathione and cysteine, as a means of investigating the aging, oxidative stress, antioxidant, chemotherapy response and toxicology processes.
Consuming Sugary Drinks During Pregnancy May Increase Asthma Risk in Mid-ChildhoodNews
Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research.READ MORE
Commonly Prescribed Painkillers: What Can be Done to Reduce Risk of Obesity and Sleep Deprivation?News
Commonly prescribed painkillers need to be given for shorter periods of time to reduce the risk of obesity and sleep deprivation, a new study has revealed.READ MORE